Comparing two heart bypass surgeries in adults with coronary artery disease
Compares hybrid keyhole bypass with stenting against standard off-pump bypass in adults.
Plain-language title generated from the registry record
Registry title: Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-pump Coronary Artery Bypass Grafting
Key facts
- Where
- Leuven, BelgiumSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07314138, who can take part
Where in Belgium
- University Hospitals LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Catharina Ziekenhuis Eindhoven
- Trial code
- NCT07314138
- Record updated
- 27 August 2026
- Original description
The MICRA-HYBRID trial is a prospective, multicenter, randomized controlled study comparing multivessel hybrid coronary revascularization (HCR) as minimally invasive arterial bypass grafting to left-sided coronary targets (LAD and LCx) plus PCI of the RCA versus conventional off-pump coronary artery bypass grafting (OPCAB) via median sternotomy in patients with three-vessel coronary artery disease. The primary goal is to evaluate whether multivessel-HCR provides superior 30-day "textbook" clinical outcomes (mortality, MI, stroke, re-exploration for bleeding, and other complications) while improving perioperative recovery and long-term cardiovascular outcomes.Read full original descriptionShow less
MICRA-HYBRID Trial: A Randomized Controlled Trial of 'Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-Pump Coronary Artery Bypass Grafting'
The MICRA-HYBRID trial is a prospective, multicenter, randomized controlled study comparing multivessel hybrid coronary revascularization (HCR) as minimally invasive arterial bypass grafting to left-sided coronary targets (LAD and LCx) plus PCI of the RCA versus conventional off-pump coronary artery bypass grafting (OPCAB) via median sternotomy in patients with three-vessel coronary artery disease. The primary goal is to evaluate whether multivessel-HCR provides superior 30-day "textbook" clinical outcomes (mortality, MI, stroke, re-exploration for bleeding, and other complications) while improving perioperative recovery and long-term cardiovascular outcomes.
Inclusion: Patients with three-vessel disease (either angiographic stenoses >70% or a fractional flow reserve value ≤0.80); Left main diameter stenosis ≥50% or a left main intravascular ultrasound minimal luminal area of ≤4.5 mm2 or fractional flow reserve value ≤0.80 combined with significant CAD of the right coronary artery.
Exclusion: RCA stenosis with high-risk clinical features requiring urgent PCI or surgical revasculari-zation; Reverse hybrid coronary revascularization, defined as PCI-RCA followed by surgical re-vascularization; Indication for concomitant cardiac surgery (e.g. valve or arrhythmia surgery) or non-cardiac surgery; Previous thoracic or cardiac surgery, mediastinal irradiation, significant trauma to the chest; Acute cardiac ischemia necessitating immediate intervention; Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure) or cancer; History of pericarditis; eGFR < 30 ml/min; Age < 18 or > 85 years; A potential participant who meets any of the following criteria will be excluded from participation in this study:; Chronic total occlusion of the RCA; In-stent RCA restenosis; EF < 30 %; Hemodynamically significant left subclavian stenosis; Severe chest wall deformities; Body mass index > 40 Kg/m2.